Nick Talken started a 3D printing materials company in a trailer lab in his co-founder's backyard, sold it to a 145-year-old German chemical giant, then spun out an AI platform that's now transforming R&D for Fortune 100 companies. Albert Invent's foundational AI model—trained on 15 million molecular structures—is helping scientists at companies like Kenvue (maker of Tylenol, Neutrogena, and Listerine) compress projects from 3 months to 2 days. We dig into how enterprises train bespoke AI models on proprietary data, why you can't just use ChatGPT for chemistry, and what becomes possible when AI can "think like a chemist."
Subscribe to The Neuron newsletter: https://theneuron.ai
Albert Invent website: https://www.albertinvent.com
Kenvue partnership announcement: https://www.businesswire.com/news/home/20251014240355/en/
